News and Announcements
Phylogica and cubist collaborate to evaluate antimicrobial phylomers
- Published July 26, 2013 9:07AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
PERTH, AUSTRALIA: July 25th 2013. Phylogica Ltd (ASX: PYC, XETRA: PH7) a leading Australian peptide drug discovery company, announces a collaboration with Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) to evaluate several of its antimicrobial Phylomers in models of multi-drug resistant bacterial infections.
“I am delighted to have the opportunity to collaborate with one of the world’s leading developers of antimicrobial drugs,” said Phylogica’s Chief Scientific Officer Dr Paul Watt. “Through this collaboration, we hope that Phylogica’s antimicrobial Phylomers will support Cubist’s ongoing work to discover and develop new antibiotics to address the growing global health threat of antibiotic resistance. In Phylogica’s own assays, these antimicrobials have shown activity against multi-resistant isolates of Gram- negative organisms, which are a major cause of deaths from hospital acquired infections of burn wounds”.
To read the full ASX announcement, please download the document below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
